What is SYROS PHARMACEUTICALS INC's earnings per share (EPS)?

SYROS PHARMACEUTICALS INC (SYRS) reported diluted earnings per share of -$5.81 for fiscal year 2023. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

SYROS PHARMACEUTICALS (SYRS) Financials

SYRS OTC

FY2023 annual

Revenue $9.9M -33.2% YoY

Net Income -$164.6M n/m YoY

EPS (Diluted) -$5.81 YoY not available

Free Cash Flow -$110.0M n/m YoY

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2024, ended Sep 30, 2024 Reported Oct 31, 2024 Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2024, filed Oct 31, 2024. Each column of the statement tables below links to the filing it was taken from.

SYROS PHARMACEUTICALS INC (SYRS) reported $9.9M in revenue for fiscal year 2023, down 33.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI SYRS FY2023 2026-10-25

Syros remains a development-stage business whose research bill exceeds revenue, producing cash outflows and leaving a thin equity cushion.

In FY2023, R&D was $108.2M against revenue of $9.9M, showing that the reported top line is not yet funding the development effort. Operating cash flow was -$109.7M versus free cash flow of -$110.0M, so cash use was overwhelmingly operational rather than reinvestment-heavy.

The cost base did not contract with the top line: revenue fell 33.2% from FY2022 while R&D fell only 3.4%, leaving research intensity elevated as reported activity shrank.

The balance sheet became more liability-funded: FY2023 liabilities were $151.5M against equity of $16.7M. A current ratio of 4.0x and a reported liquidity comparison of 15.3 months describe short-term coverage, but do not remove the thin equity base.

Financial Health Signals

Financial health score not available

SYROS PHARMACEUTICALS INC does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/8

SYROS PHARMACEUTICALS INC passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing

N/A

SYROS PHARMACEUTICALS INC reported a net loss of $164.6M while operations used $109.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

SYROS PHARMACEUTICALS INC reported an operating loss of $129.0M against $5.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$25.9M

YoYn/m

QoQn/m

SYROS PHARMACEUTICALS INC's EBITDA was -$25.9M in Q3 2024, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income

-$6.4M

YoYn/m

QoQn/m

SYROS PHARMACEUTICALS INC reported a net loss of $6.4M in Q3 2024. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

-$0.16

YoYn/m

QoQn/m

SYROS PHARMACEUTICALS INC earned -$0.16 per diluted share (EPS) in Q3 2024. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2024.

Cash & Balance Sheet

Cash & Debt

$58.3M

YoY-48.1%

QoQ-26.2%

5Y CAGR+11.8%

SYROS PHARMACEUTICALS INC held $58.3M in cash against $41.1M in long-term debt as of Q3 2024.

Shares Outstanding

27M

YoY+29.5%

QoQ0.0%

SYROS PHARMACEUTICALS INC had 27M shares outstanding in Q3 2024. This represents an increase of 29.5% from the same quarter a year earlier. It is unchanged from the prior quarter.

Free Cash Flow

Not reported for Q3 2024.

Dividends Per Share

Not reported for Q3 2024.

Margins & Returns

None of these metrics is reported for Q3 2024.

Capital Allocation

R&D Spending

$20.5M

YoY-27.4%

QoQ-6.5%

SYROS PHARMACEUTICALS INC invested $20.5M in research and development in Q3 2024. This represents a decrease of 27.4% from the same quarter a year earlier. Against the prior quarter it is down 6.5%.

Share Buybacks

Not reported for Q3 2024.

Capital Expenditures

Not reported for Q3 2024.

SYRS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SYRS quarterly income statement

Metric	TTM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	N/A	$9.9M-33.2%	$14.9M-36.6%	$23.5M+55.6%	$15.1M+661.5%	$2.0M-3.3%	$2.0M+86.2%	$1.1M+247.3%	$317K	N/A	N/A
R&D Expenses	$88.6M	$108.2M-3.4%	$111.9M+12.1%	$99.9M+31.3%	$76.1M+30.6%	$58.2M+16.1%	$50.2M+19.8%	$41.9M+10.8%	$37.8M+54.9%	$24.4M+123.5%	$10.9M
SG&A Expenses	$23.3M	$28.3M-3.5%	$29.3M+27.2%	$23.0M+8.0%	$21.3M-0.7%	$21.5M+32.9%	$16.2M+16.4%	$13.9M+32.8%	$10.5M+82.6%	$5.7M+128.1%	$2.5M
Operating Income	-$111.7M	-$129.0Mn/m	-$135.9Mn/m	-$99.4Mn/m	-$82.3Mn/m	-$77.7Mn/m	-$64.3Mn/m	-$54.7Mn/m	-$48.0Mn/m	-$29.8Mn/m	-$13.4M
EBITDA	N/A	-$126.7Mn/m	-$133.2Mn/m	-$96.7Mn/m	-$79.5Mn/m	-$75.2Mn/m	-$62.7Mn/m	-$53.2Mn/m	-$46.7Mn/m	-$29.2Mn/m	-$13.2M
Interest Expense	$5.3M	$5.1M+24.0%	$4.1M+5.8%	$3.9M+118.0%	$1.8M+2388.9%	$72K+7100.0%	$1K	N/A	N/A	N/A	N/A
Income Tax	N/A	$1K-66.7%	$3K+200.0%	$1K-75.0%	$4K-85.7%	$28K+16.7%	$24K+242.9%	$7K+250.0%	$2K	N/A	N/A
Net Income	-$97.8M	-$164.6Mn/m	-$94.7Mn/m	-$86.6Mn/m	-$84.0Mn/m	-$75.4Mn/m	-$62.3Mn/m	-$54.0Mn/m	-$47.7Mn/m	-$29.8Mn/m	-$13.4M
EPS (Basic)	N/A	-$5.81	-$7.49	-$13.84n/m	-$18.20	-$1.88n/m	-$1.91n/m	-$2.13	-$4.05	-$17.55n/m	-$10.26
EPS (Diluted)	-$3.07	-$5.81	-$7.49	-$13.84n/m	-$18.20	-$1.88n/m	-$1.91n/m	-$2.13	-$4.05	-$17.55n/m	-$10.26
Diluted Shares (Avg)	N/A	28M	13M	6M+35.8%	5M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Revenue	N/A	N/A	N/A	$387K	$3.8M-3.3%	$2.8M-54.9%	$3.0M-46.0%	N/A
R&D Expenses	$20.5M-27.4%	$22.0M-25.9%	$24.7M-14.3%	$21.5M	$28.3M+9.8%	$29.6M-10.5%	$28.8M+14.3%	N/A
SG&A Expenses	$5.7M-27.2%	$5.5M-24.4%	$6.3M-15.4%	$5.9M	$7.8M-3.9%	$7.2M+4.0%	$7.4M+6.6%	N/A
Operating Income	-$26.2Mn/m	-$27.4Mn/m	-$30.9Mn/m	-$27.1M	-$34.6Mn/m	-$34.0Mn/m	-$33.2Mn/m	N/A
EBITDA	-$25.9Mn/m	-$27.1Mn/m	-$30.6Mn/m	-$26.8M	-$34.0Mn/m	-$33.4Mn/m	-$32.6Mn/m	N/A
Interest Expense	$1.3M+0.7%	$1.4M+8.1%	$1.3M+7.4%	$1.3M	$1.3M+24.0%	$1.3M+30.3%	$1.2M+24.7%	N/A
Net Income	-$6.4Mn/m	-$23.3Mn/m	-$3.7Mn/m	-$64.4M	-$40.1Mn/m	-$36.3Mn/m	-$23.8Mn/m	N/A
EPS (Basic)	-$0.16n/m	-$0.59n/m	-$0.10n/m	-$2.22	-$1.43	-$1.30	-$0.85	N/A
EPS (Diluted)	-$0.16n/m	-$0.59n/m	-$0.10n/m	-$2.22	-$1.43	-$1.30	-$0.85	N/A
Diluted Shares (Avg)	39M+40.5%	39M+40.7%	39M+40.0%	N/A	28M	28M	28M	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

SYRS Balance Sheet

SYRS quarterly balance sheet

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$168.2M-31.2%	$244.5M+33.6%	$182.9M-14.2%	$213.3M+42.2%	$150.0M+40.5%	$106.8M+36.0%	$78.5M-14.1%	$91.3M+109.3%	$43.6M	N/A
Current Assets	$145.0M-31.4%	$211.4M+54.8%	$136.6M-23.5%	$178.6M+55.9%	$114.5M+12.6%	$101.7M+39.1%	$73.2M-14.4%	$85.5M+134.6%	$36.4M	N/A
Cash & Equivalents	$139.5M-16.7%	$167.5M+81.4%	$92.3M-46.9%	$174.0M+319.8%	$41.4M-16.9%	$49.9M+54.9%	$32.2M-45.0%	$58.6M+63.2%	$35.9M-40.5%	$60.4M
Short-Term Investments	$0-100.0%	$34.8M-8.5%	$38.1Mn/m	$0-100.0%	$50.0M+0.4%	$49.8M+25.0%	$39.8M+59.3%	$25.0Mn/m	$0n/m	$0
Accounts Receivable	N/A	N/A	N/A	$7K-100.0%	$20.0M	N/A	N/A	$867K	N/A	N/A
Long-Term Investments	$0n/m	$0-100.0%	$13.0Mn/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Total Liabilities	$151.5M+29.8%	$116.8M+19.5%	$97.7M-20.4%	$122.7M+73.3%	$70.8M+151.2%	$28.2M+114.1%	$13.2M+22.8%	$10.7M-88.3%	$91.6M	N/A
Current Liabilities	$36.7M+19.2%	$30.8M-2.3%	$31.5M+10.1%	$28.6M+21.7%	$23.5M+20.4%	$19.5M+57.3%	$12.4M+29.7%	$9.6M+20.2%	$8.0M	N/A
Non-Current Liabilities	$114.8M+33.6%	$86.0M+29.8%	$66.2M-29.6%	$94.1M+99.0%	$47.3M+446.5%	$8.7M+1051.9%	$751K-34.9%	$1.2M-98.6%	$83.6M	N/A
Long-Term Debt	$34.6M-15.0%	$40.6M+1.0%	$40.3M+1.8%	$39.6M	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.7M-87.0%	$127.7M+49.9%	$85.2M-5.9%	$90.6M+14.4%	$79.2M+0.8%	$78.6M+20.3%	$65.3M-19.0%	$80.6Mn/m	-$48.0Mn/m	-$21.8M
Retained Earnings	-$722.8Mn/m	-$558.2Mn/m	-$463.6Mn/m	-$377.0Mn/m	-$293.0Mn/m	-$217.5Mn/m	-$155.3Mn/m	-$101.3Mn/m	-$53.5M	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Total Assets	$85.0M-42.5%	$106.7M-41.0%	$134.7M-34.4%	$168.2M-31.2%	$147.8M-48.1%	$181.0M+43.4%	$205.3M+35.0%	$244.5M+33.6%
Current Assets	$63.9M-47.8%	$84.9M-44.4%	$112.2M-35.4%	$145.0M-31.4%	$122.5M-51.4%	$152.6M+66.0%	$173.6M+49.1%	$211.4M+54.8%
Cash & Equivalents	$58.3M-48.1%	$79.0M-31.6%	$83.5M-20.3%	$139.5M-16.7%	$112.2M-34.6%	$115.4M+95.5%	$104.8M+50.6%	$167.5M+81.4%
Short-Term Investments	$0n/m	$0-100.0%	$24.8M-59.4%	$0-100.0%	$0-100.0%	$28.5M+4.8%	$61.0M+50.0%	$34.8M-8.5%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0-100.0%	$0-100.0%
Total Liabilities	$96.1M-13.8%	$113.1M+4.9%	$119.7M+21.4%	$151.5M+29.8%	$111.5M-28.3%	$107.7M+13.2%	$98.6M+10.3%	$116.8M+19.5%
Current Liabilities	$28.4M0.0%	$24.5M-13.6%	$37.3M+58.4%	$36.7M+19.2%	$28.4M-26.1%	$28.4M-27.1%	$23.6M-14.6%	$30.8M-2.3%
Non-Current Liabilities	$67.7M-18.5%	$88.6M+11.6%	$82.4M+9.8%	$114.8M+33.6%	$83.1M-29.1%	$79.4M+41.0%	$75.0M+21.5%	$86.0M+29.8%
Long-Term Debt	$41.1M+4.3%	$40.9M0.0%	$29.7M-24.1%	$34.6M-15.0%	$39.4M-2.7%	$40.9M+20.5%	$39.1M+0.9%	$40.6M+1.0%
Total Equity	-$11.1M-130.6%	-$6.4M-108.7%	$15.1M-85.9%	$16.7M-87.0%	$36.3M-71.9%	$73.2M+136.1%	$106.8M+70.1%	$127.7M+49.9%
Retained Earnings	-$756.2Mn/m	-$749.8Mn/m	-$726.5Mn/m	-$722.8Mn/m	-$658.4Mn/m	-$618.3Mn/m	-$582.0Mn/m	-$558.2Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill.

SYRS Cash Flow Statement

SYRS quarterly cash flow statement

Metric	TTM	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$100.0M	-$109.7Mn/m	-$123.1Mn/m	-$99.5Mn/m	-$57.4Mn/m	-$60.3Mn/m	-$40.3Mn/m	-$44.7Mn/m	-$40.5Mn/m	-$23.0Mn/m	-$12.0M
Depreciation & Amortization	N/A	$2.3M-16.8%	$2.7M-1.9%	$2.8M-0.6%	$2.8M+10.0%	$2.5M+57.2%	$1.6M+5.0%	$1.5M+20.0%	$1.3M+111.5%	$602K+133.3%	$258K
Stock-Based Compensation	N/A	$10.4M-8.6%	$11.4M+10.2%	$10.4M-5.3%	$10.9M+11.2%	$9.8M+48.9%	$6.6M+49.6%	$4.4M+4.4%	$4.2M+31.0%	$3.2M+245.0%	$937K
Capital Expenditures	N/A	$272K-78.1%	$1.2M-0.3%	$1.2M-62.7%	$3.3M-73.6%	$12.6M+813.2%	$1.4M+68.6%	$821K-64.6%	$2.3M+97.4%	$1.2M+485.1%	$201K
Free Cash Flow	N/A	-$110.0Mn/m	-$124.3Mn/m	-$100.8Mn/m	-$60.7Mn/m	-$72.9Mn/m	-$41.7Mn/m	-$45.5Mn/m	-$42.9Mn/m	-$24.2Mn/m	-$12.2M
Investing Cash Flow	$1.9M	$37.3M-44.4%	$67.2Mn/m	-$52.7M-212.8%	$46.7Mn/m	-$11.7Mn/m	-$10.6Mn/m	-$15.6Mn/m	-$27.3Mn/m	-$1.2M	N/A
Financing Cash Flow	$43.2M	$43.5M-66.8%	$131.0M+85.9%	$70.5M-50.7%	$143.0M+116.6%	$66.0M-4.5%	$69.1M+103.6%	$33.9M-62.5%	$90.6Mn/m	-$278K	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Operating Cash Flow	-$20.7Mn/m	-$29.7Mn/m	-$31.1Mn/m	-$18.6Mn/m	-$31.9Mn/m	-$22.4Mn/m	-$36.9Mn/m	-$31.1Mn/m
Depreciation & Amortization	$325K-46.9%	$331K-49.1%	$334K-47.6%	$352K-50.1%	$612K-7.1%	$650K-1.7%	$638K-6.3%	$705K-0.4%
Stock-Based Compensation	$1.6M-50.1%	$1.8M-35.9%	$2.1M-20.5%	N/A	$3.3M+10.2%	$2.8M+4.6%	$2.6M-7.6%	N/A
Capital Expenditures	N/A	N/A	N/A	$38K-94.4%	$0-100.0%	-$1K-99.1%	$235K+83.6%	$674K+175.1%
Free Cash Flow	N/A	N/A	N/A	-$18.6Mn/m	-$31.9Mn/m	-$22.4Mn/m	-$37.1Mn/m	-$31.8Mn/m
Investing Cash Flow	$0-100.0%	$25.1M-23.9%	-$24.6Mn/m	$1.5M-96.0%	$28.6M+362.5%	$32.9M+107.2%	-$25.7M-448.7%	$37.7Mn/m
Financing Cash Flow	$0n/m	$41K-70.7%	-$265Kn/m	$43.4Mn/m	-$5K-100.0%	$140Kn/m	-$53Kn/m	-$10.7M-11249.0%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

SYRS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

SYRS quarterly financial ratios

Metric	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Margin	-1298.2%	-913.1%	-423.3%	-545.3%	-3922.4%	-3136.4%	-4966.9%	-15130.3%	N/A	N/A
Net Margin	-1656.3%	-636.1%	-368.5%	-556.8%	-3804.2%	-3039.0%	-4904.6%	-15047.3%	N/A	N/A
Return on Equity	-987.7%-913.6pp	-74.1%+27.5pp	-101.6%-8.8pp	-92.8%+2.4pp	-95.2%-15.9pp	-79.3%+3.4pp	-82.7%-23.5pp	-59.2%	N/A	N/A
Return on Assets	-97.9%-59.1pp	-38.7%+8.6pp	-47.3%-7.9pp	-39.4%+10.9pp	-50.3%+8.1pp	-58.4%+10.4pp	-68.8%-16.6pp	-52.2%+16.1pp	-68.3%	N/A
Current Ratio	3.95-2.9x	6.87+2.5x	4.33-1.9x	6.24+1.4x	4.87-0.3x	5.21-0.7x	5.89-3.0x	8.94+4.4x	4.58	N/A
Debt-to-Equity	2.07+1.8x	0.32-0.2x	0.470.0x	0.44	N/A	N/A	N/A	N/A	N/A	N/A
Liabilities-to-Equity	9.09+8.2x	0.91-0.2x	1.15-0.2x	1.35+0.5x	0.89+0.5x	0.36+0.2x	0.20+0.1x	0.13	N/A	N/A
Asset Turnover	0.060.0x	0.06-0.1x	0.13+0.1x	0.07+0.1x	0.010.0x	0.020.0x	0.010.0x	0.00	N/A	N/A
FCF Margin	-1106.9%	-835.4%	-429.1%	-402.2%	-3677.6%	-2034.1%	-4137.1%	-13519.9%	N/A	N/A

Metric	Q3'2410-Q	Q2'2410-Q	Q1'2410-Q	Q4'2310-K	Q3'2310-Q	Q2'2310-Q	Q1'2310-Q	Q4'2210-K
Operating Margin	N/A	N/A	N/A	-7012.9%	-920.7%	-1200.1%	-1124.3%	N/A
Net Margin	N/A	N/A	N/A	-16636.7%	-1067.1%	-1279.8%	-805.3%	N/A
Return on Equity	N/A	N/A	-24.6%-2.3pp	-386.4%	-110.6%-87.2pp	-49.5%+61.6pp	-22.3%+17.8pp	N/A
Return on Assets	-7.5%+19.6pp	-21.9%-1.8pp	-2.8%+8.8pp	-38.3%	-27.2%-16.5pp	-20.0%+7.3pp	-11.6%+4.9pp	N/A
Current Ratio	2.25-2.1x	3.46-1.9x	3.01-4.4x	3.95-2.9x	4.31-2.3x	5.38+3.0x	7.37+3.2x	6.87+2.5x
Debt-to-Equity	N/A	N/A	1.97+1.6x	2.07+1.8x	1.09+0.8x	0.56-0.5x	0.37-0.3x	0.32-0.2x
Liabilities-to-Equity	N/A	N/A	7.95+7.0x	9.09+8.2x	3.07+1.9x	1.47-1.6x	0.92-0.5x	0.91-0.2x
Asset Turnover	N/A	N/A	N/A	0.00	0.030.0x	0.020.0x	0.010.0x	N/A
FCF Margin	N/A	N/A	N/A	-4806.2%	-846.8%	-790.2%	-1257.1%	N/A

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Where SYROS PHARMACEUTICALS INC Ranks

Frequently Asked Questions

What is SYROS PHARMACEUTICALS INC's annual revenue?

SYROS PHARMACEUTICALS INC (SYRS) reported $9.9M in total revenue for fiscal year 2023. This represents a -33.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is SYROS PHARMACEUTICALS INC's revenue growing?

SYROS PHARMACEUTICALS INC (SYRS) revenue declined by 33.2% year-over-year, from $14.9M to $9.9M in fiscal year 2023.

Is SYROS PHARMACEUTICALS INC profitable?

No, SYROS PHARMACEUTICALS INC (SYRS) reported a net loss of $164.6M in fiscal year 2023.

What is SYROS PHARMACEUTICALS INC's EBITDA?

SYROS PHARMACEUTICALS INC (SYRS) had EBITDA of -$126.7M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does SYROS PHARMACEUTICALS INC have?

As of fiscal year 2023, SYROS PHARMACEUTICALS INC (SYRS) had $139.5M in cash and equivalents against $34.6M in long-term debt.

What is SYROS PHARMACEUTICALS INC's return on equity (ROE)?

SYROS PHARMACEUTICALS INC (SYRS) has a return on equity of -987.7% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.

What is SYROS PHARMACEUTICALS INC's free cash flow?

SYROS PHARMACEUTICALS INC (SYRS) recorded an outflow of $110.0M in free cash flow during fiscal year 2023. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is SYROS PHARMACEUTICALS INC's operating cash flow?

SYROS PHARMACEUTICALS INC (SYRS) recorded an outflow of $109.7M in operating cash flow during fiscal year 2023, representing cash used by core business activities.

What are SYROS PHARMACEUTICALS INC's total assets?

SYROS PHARMACEUTICALS INC (SYRS) had $168.2M in total assets as of fiscal year 2023, including both current and long-term assets.

What are SYROS PHARMACEUTICALS INC's capital expenditures?

SYROS PHARMACEUTICALS INC (SYRS) invested $272K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.

How much does SYROS PHARMACEUTICALS INC spend on research and development?

SYROS PHARMACEUTICALS INC (SYRS) invested $108.2M in research and development during fiscal year 2023.

How many shares does SYROS PHARMACEUTICALS INC have outstanding?

SYROS PHARMACEUTICALS INC (SYRS) had 26M shares outstanding as of fiscal year 2023.

What is SYROS PHARMACEUTICALS INC's current ratio?

SYROS PHARMACEUTICALS INC (SYRS) had a current ratio of 3.95 as of fiscal year 2023, which is generally considered healthy.

What is SYROS PHARMACEUTICALS INC's debt-to-equity ratio?

SYROS PHARMACEUTICALS INC (SYRS) had a debt-to-equity ratio of 2.07 as of fiscal year 2023. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

What is SYROS PHARMACEUTICALS INC's liabilities-to-equity ratio?

SYROS PHARMACEUTICALS INC (SYRS) had a liabilities-to-equity ratio of 9.09 as of fiscal year 2023, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

What is SYROS PHARMACEUTICALS INC's return on assets (ROA)?

SYROS PHARMACEUTICALS INC (SYRS) had a return on assets of -97.9% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

How does SYROS PHARMACEUTICALS INC's liquidity compare with its operating cash outflow?

At the end of fiscal year 2023, SYROS PHARMACEUTICALS INC (SYRS) held $139.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $109.7M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is SYROS PHARMACEUTICALS INC's Piotroski F-Score?

SYROS PHARMACEUTICALS INC (SYRS) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are SYROS PHARMACEUTICALS INC's earnings high quality?

SYROS PHARMACEUTICALS INC (SYRS) reported a net loss of $164.6M while operations used $109.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can SYROS PHARMACEUTICALS INC cover its interest payments?

SYROS PHARMACEUTICALS INC (SYRS) reported an operating loss of $129.0M against $5.1M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.